Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry. J of Skin. 2024;8(6):s450. doi:10.25251/skin.8.supp.450